Introduction
Hematological neoplasias have been shown to be excellent targets for immunotherapy. Both allogeneic stem cell transplantation, and donor lymphocyte infusion, as an anticancer treatment for various hematological malignancies, demonstrate the potential of the immune system. [1] [2] [3] [4] [5] [6] [7] However, allogeneic stem cell transplantation is not a suitable treatment option for the majority of patients with hematological malignancies and thus adoptive immunotherapy approaches have been explored in an attempt to harness this immune effect while reducing toxicity.
Recently, a pilot study in patients with indolent B-cell Non-Hodgkin lymphomas reported the use of genemodified autologous T cells targeting the B-cell antigen CD20. This was the first time that chimeric T cells had been applied in humans for lymphoma treatment, and the trial demonstrated safety and clinical activity. 8 This study confirmed the clinical utility of antigen-specific T-cell therapy that has previously been demonstrated in Hodgkin lymphoma when targeting Epstein-Barr virusrelated antigens. 9 Efficacy of T-cell immunotherapy with ex vivo expanded tumor infiltrating lymphocytes or genemodified T cells has also been demonstrated in solid tumors, particularly against melanoma. 10, 11 Compared with the process of collecting and processing tumor infiltrating lymphocytes, the technique of using transduced T cells that express a chimeric receptor recognizing a tumor antigen is potentially more easily and widely applicable.
A range of different chimeric receptor constructs have been described. The majority of these constructs consist of a single-chain antibody (scFv) as the extracellular targeting domain. This is linked to a transmembrane region and an intracellular signaling domain, usually the CD3 zeta chain. These constructs allow redirection of T-cell activity to a pre-defined target antigen regardless of the antigen specificity of the 'natural' T-cell receptor and major histocompatibility complex expression of the target cells. [12] [13] [14] In this article, we describe the use a retroviral vector encoding a chimeric T-cell receptor binding the carbohydrate antigen Lewis Y (Le Y ). The vector construct has been described before in detail by Westwood et al. 15 An important advantage of this particular construct is that its sequence is fully humanized and therefore less immunogenic than constructs containing murine elements. [16] [17] [18] Furthermore, besides CD3 zeta, it contains a co-stimulatory signaling motif from the CD28 co-receptor, which has previously been demonstrated to enhance T-cell activation compared with CD3 zeta alone. 19, 20 A further advantage of Le Y as a target structure is that anti-Le Y chimeric receptor expressing T cells could potentially target a broad range of malignancies that express Le Y . [21] [22] [23] [24] Lewis Y as a tumor-associated antigen has been shown to be correlated with an adverse prognosis in patients with lung cancer 25 and to have a pathogenetic role in colon cancer, 22 whereas expression and functional data are so far lacking for hematological diseases. Our group recently described in vitro and in vivo activity of gene-modified T cells expressing a chimeric receptor targeting Le Y against solid tumors.
15
In this study, we have investigated the activity of T cells expressing the anti-Le Y chimeric receptor against hematological targets. We show expression of the Le Y antigen on a subset of multiple myeloma (MM) patient samples and cell lines as well as acute myeloid leukemia (AML) blasts. We further demonstrate specific in vitro and in vivo antitumor activity of T cells expressing the anti-LeY chimeric receptor.
Results

Lewis Y antigen expression in cell lines of MM and AML
It has been stated that Le
Y is expressed on early myeloid progenitor cells and corresponding CD34-positive leukemia cell lines. 26 Figure 7 ). We were unable to perform an equivalent Table 1 Characteristics of patients with MM and AML whose bone marrow samples were assessed for Le The disease infiltration rate was determined morphologically in the biopsy for patients with MM and in the BM aspirate for patients with AML. Chimeric T cells for Lewis Y-positive MM and AML S Peinert et al experiment using an AML mouse model. Although a murine AML model with the K562 cell line has been described, concordant with reports in the literature, [26] [27] [28] we found the disease kinetics of the K562 AML mouse model far more variable and less reliable to perform comparative in vivo studies.
Chimeric T cells for Lewis Y-positive MM and AML S Peinert et al
Discussion
We have previously demonstrated activity of T cells expressing a chimeric receptor directed against Le Y in vitro and in vivo against epithelial tumors. 15 In this study, we demonstrate that the expression of Le Y is not restricted to epithelial tumors but is also found on AML and MM. Given the previously documented expression of Le Y on mature neutrophils, 24, 29 the finding that it is also expressed on AML blasts is not entirely surprising. In contrast, the expression on plasma cells was rather Y as a target antigen for the treatment of MM and AML. We established a Good Manufacturing Practicecompliant transduction protocol, which resulted in effective gene transduction into both CD4-and CD8-positive T-cell populations. The presence of antigenspecific CD4 and CD8 T cells in the adoptively transferred T-cell product is likely to be required for maximum efficacy. 34 Furthermore, we were able to demonstrate that T cells expressing the anti-Le Y singlechain receptor were highly specific for Le Our study reveals the previously unreported expression of the carbohydrate antigen Le Y on AML and MM. Furthermore, we have shown in vitro and in vivo efficacy of a novel cellular immunotherapy using T cells expressing the chimeric anti-Le Y receptor. Our results confirm that Le Y is a suitable antigen for T-cell-mediated immunotherapy against both MM and AML. The safety of this approach is supported by the favorable toxicity profile of various 'naked' and conjugated anti-Le Y antibodies in early phase clinical studies, as well as the lack of transforming events in T cells retrovirally transduced to express this construct. [37] [38] [39] [40] An alternative to the use of chimeric T cells for the treatment of Le Y expressing malignancies is the less cumbersome utilization of monoclonal antibodies. [38] [39] [40] However, chimeric T cells as used in this study effectively combine antigen specificity with direct activation of the most potent immune effector cells upon antigen binding. Therefore, in our opinion, chimeric T cells are more likely to mount 
Materials and methods
Cells
RPMI-8226, NCI-H929, U266, OPM-2 and LP-1 are MM cell lines, K562, KG-1 and KG-1A are AML cell lines (all from American Type Culture Collection, Manassas, VA, USA) with K562 being derived from CML in blast crisis (erythroleukemia). We established the AMLCC1 cell line from primary blasts taken from peripheral blood of an AML patient. All tumor cell lines were cultured in complete medium composed of RPMI medium 1640, 10% heat-inactivated fetal calf serum, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, 50 mg ml À1 gentamicin and 2 mM glutamine (all from Invitrogen, Carlsbad, CA, USA). T cells were cultured in the same medium with the addition of 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 5 Â 10 À5 M 2-mercaptoethanol (Invitrogen) and 600 U ml À1 human recombinant interleukin-2 (National Cancer Institute, Frederick, MD, USA and Chiron, Emeryville, CA, USA). RPMI 8226-13 cells were generated by sorting for highly Le Y -expressing RPMI-8226 cells per FACS and initially passaged twice subcutaneously in NOD-SCID mice to establish a cell line that reproducibly formed subcutaneous tumors on subsequent injection into mice.
Chimeric receptor construct and retroviral vector production
DNA encoding the anti-Le Y chimeric receptor was generated by using standard molecular biology techniques using an scFv 16 generated from the humanized monoclonal antibody hu3S193. 41 The construct used in this study was derived from the one described by Westwood et al. 15 by excising the sequences coding for the Neomycin (Neo)-resistance gene and the IRES sequence by cutting at the HindIII/SpHI sites and subsequent religation. Removal of these sequences simplified the vector and eliminated translation of the Neo-resistance gene, thereby rendering the vector less immunogenic for potential subsequent use in humans (see also Figure 8 ). The construct was transfected into PA317 and GP+E86 packaging lines and resulting retroviral supernatants used to repeatedly (four times) transduce both packaging lines ('ping-pong'). The resulting GP+E86 supernatant was used to transduce the PG13 packaging line (four times). In the absence of a selectable marker, the transduced PG13 packaging line was enriched for cTCR-expressing cells by immunomagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) targeting the chimeric receptor according to the manufacturer's instructions. The enriched cells were then subcloned and a potential high-titer producer clone was identified by flow cytometry by staining for cTCR expression on the packaging cells. From this clone, a master cell bank was generated and clinical grade retroviral supernatant produced commercially under code of Good Manufacturing Practice (cGMP) conditions (EUFETS, Idar-Oberstein, Germany).
T-cell transduction and expansion
Human peripheral blood mononuclear cells were isolated from normal donor apheresis products, buffy coats or patients' peripheral blood. Briefly, peripheral blood mononuclear cells were stimulated with anti-human CD3 (OKT3 30 ng ml
À1
, Ortho Biotech, Bridgewater, NJ, USA) and human recombinant interleukin-2 (Biological Resources Branch Preclinical Repository, NCI, Frederick, MD, USA) at 600 U ml À1 for 3 days. Retroviral transduction was performed by incubation with supernatant from the PG13 retroviral producer cell line on a Retronectin (Takara Bio, Otsu, Japan) matrix as per the manufacturer's instructions. Briefly, Retronectin was coated at a concentration of 6 mg cm À2 in non-tissue culture six-well plates (Becton Dickinson, Franklin Lakes, NJ, USA) and incubated with 5 ml of retroviral supernatant. After 4 h, supernatant was removed and 2.5 Â 10 6 T cells in 5 ml of complete media added for 12 h. This procedure was repeated once on the next day. Following transduction, cells were expanded for up to 21 days. During expansion, a cell density of 2 Â 10 6 /ml was maintained. Transduction efficacy was determined on day 8 or 10 after transduction by flow cytometry (FACS, see below). T-cell cultures were performed in AIMV medium (Invitrogen) supplemented with 2% human serum (BioWhittaker, Cambrex Bioscience, Walkersville, MD, USA).
In order to use Le Y expression as a target for T-cell-based immunotherapy of MM and AML, we generated a retroviral vector as previously described. 15 In consideration of a future clinical application, the selective marker (Neo) and the preceding IRES sequence were deleted from the original construct. A cGMP-conform master cell bank was created and clinical grade supernatant was used for subsequent transduction of primary human T cells. The retroviral titer of the clinical grade supernatant was determined to be B7.5 Â 10 6 CFU ml À1 based on FACS and molecular methods (quantitative PCR) by the manufacturer (EUFETS GmbH, Idar-Oberstein, Germany).
Antibodies and flow cytometry to examine T-cell transduction
Expression of the chimeric receptor was determined by staining with a mouse monoclonal antibody designated LMH-3 IgG1 specific for the idiotype of the scFv (anti-3S193 idiotype), 42 supplied by Ludwig Institute for Cancer Research (LICR), followed by phycoerythrin (PE)-conjugated anti-mouse Ig F(ab') 2 (Chemicon, Billerica, MA, USA). Cell surface phenotyping of YÀ fluorescein isothiocyanate antibody (Chemicon). MM cells were identified by staining for CD138 (CD138APC, 5 ml, undiluted) and CD38 fluorescein isothiocyanate (10 ml, undiluted, both Becton Dickinson) versus side scatter. Myeloid blast cells were identified by gating for blasts in the CD45 versus side scatter plot. Chronic lymphocytic leukemia cells were identified by gating for lymphocytes in the CD45 versus side scatter plot and staining for CD5 (CD5 PE, clone L17F12, Becton Dickinson) and CD19 PerCP-Cy5.5 (Clone SJ25C1, Becton Dickinson). Sézary cells were identified by staining for CD3 (anti-CD3 PerCP, clone SK7, Becton Dickinson), CD4 (anti-CD4-fluorescein isothiocyanate, clone SK3, Becton Dickinson) and CD8 (anti-CD8-PE, clone SK1, Becton Dickinson). Cells were stained for 15 min at room temperature in the dark, red cells were lysed with FACS Lysis buffer (Becton Dickinson, 1 ml). Then stained cells were washed twice in phosphate-buffered saline and resuspended in 1 ml of phosphate-buffered saline for FACS analysis. The MFI above the background MFI of the isotype control was determined for plasma cells or myeloblasts, respectively, and compared with the MFI of containing lymphocytes (MFI lymph) that served as internal negative control compensating for variations in absolute fluorescence intensity levels due to use of two different FACS instruments. The definition of Le Y positivity required a tumor cell MFI at least five times higher than the MFI of the lymphocytes (MFI lymph) and was based on functional data of anti-Le Y T cells.
Correlation of patient and disease characteristics with Le Y expression
The following clinical and routine laboratory parameters of both MM and AML patients were recorded on the day of the BM biopsy for investigation of Le Y expression: age, gender, number of lines of prior treatment, hemoglobin, neutrophil and platelet count. For patients with MM, the following characteristics were also analyzed: heavy and light chain isotype of the paraprotein, presence or absence of plasmablastic or leukemic disease, extramedullary disease, adverse cytogenetics of 13q deletion and/or t(4;14), p53 mutation (by immunohistochemistry of BM biopsy), levels of b 2 -microglobulin and albumin in plasma and percentage of plasma cells/plasmablasts in the BM biopsy. For patients with AML, additional characteristics analyzed were: AML subtype according to the WHO classification, 43 presence or absence of adverse cytogenetics (-7, -5, trisomy 8, abnormal 3q, t(6;9), t(9;22), 11q23 abnormalities), increased lactate dehydrogenase levels, white blood cell count 4or p30 Â 10 9 /l, and percentage of myeloblasts in the nucleated cell fraction of the BM aspirate.
For all patients included in the analysis, the medical history was reviewed independently by two investigators (HMP and SP) in order to determine the clinical status of the patients' disease at the time of the BM biopsy. On the basis of this information, each patient's disease was classified as being clinically high risk (rapidly progressive or treatment refractory) or not high risk. Each of the above listed characteristics was analyzed for correlation with Le Y antigen expression in a univariate analysis (unpaired t-test; GraphPad Software, La Jolla, CA, USA).
Correlation of Le
Y expression and tumor cell lysis and two-tailed P-values were determined (GraphPad Software).
Cytokine secretion and cytotoxicity assays T-cell antitumor response assays were performed as described. 44 Briefly, IFN-g secretion was determined by enzyme-linked immunosorbent assay on culture supernatants following overnight co-culture of transduced T cells (1 Â 
